IBDEI0KF ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,9012,1,4,0)
 ;;=4^N01.0
 ;;^UTILITY(U,$J,358.3,9012,2)
 ;;=^5015501
 ;;^UTILITY(U,$J,358.3,9013,0)
 ;;=N01.1^^69^617^68
 ;;^UTILITY(U,$J,358.3,9013,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9013,1,3,0)
 ;;=3^Rapidly progr neph synd w/ focal & seg glomerular lesions
 ;;^UTILITY(U,$J,358.3,9013,1,4,0)
 ;;=4^N01.1
 ;;^UTILITY(U,$J,358.3,9013,2)
 ;;=^5015502
 ;;^UTILITY(U,$J,358.3,9014,0)
 ;;=N01.2^^69^617^66
 ;;^UTILITY(U,$J,358.3,9014,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9014,1,3,0)
 ;;=3^Rapidly progr neph synd w/ diffuse membranous glomrlneph
 ;;^UTILITY(U,$J,358.3,9014,1,4,0)
 ;;=4^N01.2
 ;;^UTILITY(U,$J,358.3,9014,2)
 ;;=^5015503
 ;;^UTILITY(U,$J,358.3,9015,0)
 ;;=N01.3^^69^617^64
 ;;^UTILITY(U,$J,358.3,9015,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9015,1,3,0)
 ;;=3^Rapidly progr neph synd w/ diffus mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,9015,1,4,0)
 ;;=4^N01.3
 ;;^UTILITY(U,$J,358.3,9015,2)
 ;;=^5015504
 ;;^UTILITY(U,$J,358.3,9016,0)
 ;;=N01.4^^69^617^63
 ;;^UTILITY(U,$J,358.3,9016,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9016,1,3,0)
 ;;=3^Rapidly progr neph synd w/ diffus endocaplry prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,9016,1,4,0)
 ;;=4^N01.4
 ;;^UTILITY(U,$J,358.3,9016,2)
 ;;=^5015505
 ;;^UTILITY(U,$J,358.3,9017,0)
 ;;=N01.5^^69^617^67
 ;;^UTILITY(U,$J,358.3,9017,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9017,1,3,0)
 ;;=3^Rapidly progr neph synd w/ diffuse mesangiocap glomrlneph
 ;;^UTILITY(U,$J,358.3,9017,1,4,0)
 ;;=4^N01.5
 ;;^UTILITY(U,$J,358.3,9017,2)
 ;;=^5015506
 ;;^UTILITY(U,$J,358.3,9018,0)
 ;;=N01.6^^69^617^62
 ;;^UTILITY(U,$J,358.3,9018,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9018,1,3,0)
 ;;=3^Rapidly progr neph synd w/ dense deposit disease
 ;;^UTILITY(U,$J,358.3,9018,1,4,0)
 ;;=4^N01.6
 ;;^UTILITY(U,$J,358.3,9018,2)
 ;;=^5015507
 ;;^UTILITY(U,$J,358.3,9019,0)
 ;;=N01.7^^69^617^65
 ;;^UTILITY(U,$J,358.3,9019,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9019,1,3,0)
 ;;=3^Rapidly progr neph synd w/ diffuse crescentic glomrlneph
 ;;^UTILITY(U,$J,358.3,9019,1,4,0)
 ;;=4^N01.7
 ;;^UTILITY(U,$J,358.3,9019,2)
 ;;=^5015508
 ;;^UTILITY(U,$J,358.3,9020,0)
 ;;=N01.8^^69^617^70
 ;;^UTILITY(U,$J,358.3,9020,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9020,1,3,0)
 ;;=3^Rapidly progr neph synd w/ oth morphologic changes
 ;;^UTILITY(U,$J,358.3,9020,1,4,0)
 ;;=4^N01.8
 ;;^UTILITY(U,$J,358.3,9020,2)
 ;;=^5015509
 ;;^UTILITY(U,$J,358.3,9021,0)
 ;;=N01.9^^69^617^71
 ;;^UTILITY(U,$J,358.3,9021,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9021,1,3,0)
 ;;=3^Rapidly progr neph synd w/ unsp morphologic changes
 ;;^UTILITY(U,$J,358.3,9021,1,4,0)
 ;;=4^N01.9
 ;;^UTILITY(U,$J,358.3,9021,2)
 ;;=^5015510
 ;;^UTILITY(U,$J,358.3,9022,0)
 ;;=N02.0^^69^617^79
 ;;^UTILITY(U,$J,358.3,9022,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9022,1,3,0)
 ;;=3^Recurrent & perst hematur w/ minor glomerular abnlt
 ;;^UTILITY(U,$J,358.3,9022,1,4,0)
 ;;=4^N02.0
 ;;^UTILITY(U,$J,358.3,9022,2)
 ;;=^5015511
 ;;^UTILITY(U,$J,358.3,9023,0)
 ;;=N02.1^^69^617^78
 ;;^UTILITY(U,$J,358.3,9023,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9023,1,3,0)
 ;;=3^Recurrent & perst hematur w/ focal & seg glomerular lesions
 ;;^UTILITY(U,$J,358.3,9023,1,4,0)
 ;;=4^N02.1
 ;;^UTILITY(U,$J,358.3,9023,2)
 ;;=^5015512
 ;;^UTILITY(U,$J,358.3,9024,0)
 ;;=N02.2^^69^617^76
 ;;^UTILITY(U,$J,358.3,9024,1,0)
 ;;=^358.31IA^4^2
